Clinical Guidelines

Romiplostim May Improve Chemotherapy-Induced Thrombocytopenia in Patients With GI Cancers

Romiplostim was beneficial in treating chemotherapy-induced thrombocytopenia, according to findings from the global phase III RECITE trial published in The New England Journal of Medicine.  

Share

Romiplostim has shown promise in treating chemotherapy-induced thrombocytopenia, based on the phase III RECITE trial results published in The New England Journal of Medicine. Led by Dr. Hanny Al-Samkari, the study aims to address the severe bleeding risk associated with this condition, which often forces oncologists to reduce or delay chemotherapy, negatively impacting patient outcomes. The trial involved 165 patients with gastrointestinal cancers, demonstrating significant improvements in maintaining chemotherapy doses without modifications, indicating potential for enhanced patient survival.

Original Source(s)

Romiplostim May Improve Chemotherapy-Induced Thrombocytopenia in Patients With GI Cancers

  • by The ASCO Post Staff

  • March 17, 2026

Related Content

Targeted NGS Streamlines Myeloproliferative Neoplasm Diagnostics

Kritika Krishnamurthy shares real-world experience on advanced MPN genomic profiling

  • March 18, 2026

  • 9 min
Register Today for Roswell Park’s Upstate New York Hematology & Hematologic Oncology Conference

Register for the Upstate New York Hematology & Hematologic Oncology Conference: A Review of the 67th ASH Annual meeting, taking place on April 25-26 in Buffalo, NY.

  • by

  • March 13, 2026

  • 1 min
Enhancing Immune Thrombocytopenia Education and Support: Insights From a Learning Exchange Program